Dr. Desiree van der Heijde, with Leiden University Medical Centre in the Netherlands, and colleagues elsewhere examined outcomes at week 204 in patients who were randomized to certolizumab pegol or placebo as part of the phase III RAPID-axSpA trial. The cohort included patients with radiographic axial spondyloarthritis (axSpA) and non-radiographic-axSpA. Previous reports have shown that […]
